Literature DB >> 20651057

Personalized tamoxifen: a step closer but miles to go.

Aditya Bardia1, Vered Stearns.   

Abstract

Genetic variants in CYP2D6 lead to reduced conversion of tamoxifen to the active metabolite endoxifen. However, the role of the CYP2D6 genotype in predicting tamoxifen-associated outcomes remains controversial. Accurate assignment of the CYP2D6 genotype in archival tissues is crucial for future studies attempting to determine risk prediction of outcomes in tamoxifen-treated individuals.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20651057      PMCID： PMC2980759          DOI： 10.1158/1078-0432.CCR-10-1506

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise.

Authors:  M S Bray; E Boerwinkle; P A Doris
Journal:  Hum Mutat       Date:  2001-04       Impact factor: 4.878

2.  CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.

Authors:  Werner Schroth; Ute Hamann; Peter A Fasching; Silke Dauser; Stefan Winter; Michel Eichelbaum; Matthias Schwab; Hiltrud Brauch
Journal:  Clin Cancer Res       Date:  2010-06-01       Impact factor: 12.531

3.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

4.  MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET).

Authors:  Malgorzata Jaremko; Christina Justenhoven; Benny K Abraham; Werner Schroth; Peter Fritz; Sandra Brod; Caren Vollmert; Thomas Illig; Hiltrud Brauch
Journal:  Hum Mutat       Date:  2005-03       Impact factor: 4.878

5.  Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.

Authors:  Silvana Borges; Zeruesenay Desta; Yan Jin; Azzouz Faouzi; Jason D Robarge; Sanosh Philips; Santosh Philip; Anne Nguyen; Vered Stearns; Daniel Hayes; James M Rae; Todd C Skaar; David A Flockhart; Lang Li
Journal:  J Clin Pharmacol       Date:  2010-01-15       Impact factor: 3.126

6.  The biology of hormone refractory breast and prostate cancer: An NCI workshop report.

Authors:  Suresh Mohla; Vered Stearns; Neeraja Sathyamoorthy; Michael G Rosenfeld; Peter Nelson
Journal:  Cancer Biol Ther       Date:  2009-11-26       Impact factor: 4.742

7.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors:  Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

8.  Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples.

Authors:  James M Rae; Kevin E Cordero; Joshua O Scheys; Marc E Lippman; David A Flockhart; Michael D Johnson
Journal:  Pharmacogenetics       Date:  2003-08

9.  Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.

Authors:  Matthew P Goetz; Vera J Suman; Fergus J Couch; Matthew M Ames; James M Rae; Mark G Erlander; Xiao-Jun Ma; Dennis C Sgroi; Carol A Reynolds; Wilma L Lingle; Richard M Weinshilboum; David A Flockhart; Zeruesenay Desta; Edith A Perez; James N Ingle
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

10.  Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.

Authors:  Yan Jin; Daniel F Hayes; Lang Li; Jason D Robarge; Todd C Skaar; Santosh Philips; Anne Nguyen; Anne Schott; Jill Hayden; Suzanne Lemler; Anna Maria Storniolo; David A Flockhart; Vered Stearns
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.